• Presentation of data from the INTEGUMENT-INFANT trial of investigational ZORYVE cream 0.05% in infants ages 3 to <24 months, where treatment options remain limited
  • New analyses from the ARRECTOR and DERMIS-1/2 trials further demonstrate ZORYVE’s efficacy and symptom improvements across the body in individuals with psoriasis
  • Additional data from collaborative research reinforce the inflammatory pathway and barrier impairment involved in seborrheic dermatitis
  • Real-world research examines the role long-term topical corticosteroid use plays in the care of adults and children with chronic inflammatory skin conditions